AUSTIN, Texas, Jan. 3, 2013 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. announced today that a new audio interview with PositiveID Corporation PSID, an emerging growth company and developer of airborne bio-threat detection systems for America's homeland defense industry as well as advanced technologies for rapid medical testing and diabetes management, is now available. The interview can be heard at http://smallcapvoice.com/blog/12-26-12-smallcapvoice-interview-with-positiveid-corporation-psid.
William J. Caragol, Chairman and CEO of PositiveID, stated, "By entering into this teaming agreement with such a world-class company, we believe we have positioned our unique M-BAND system to be an integral component of the upcoming $3.1 billion BioWatch Gen-3 system procurement. We will also maintain our role as the exclusive provider of assays and reagents under the teaming agreement for this important homeland defense program."
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
SIGN UP FOR OUR FREE STOCK ALERTS http://www.smallcapvoice.com/newsletter.html
Like us on Facebook http://www.facebook.com/pages/SmallCapVoice/101910803171
Follow us on Twitter https://twitter.com/#!/smallcapvoice
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of airborne bio-threat detection systems for America's homeland defense industry as well as advanced technologies for rapid medical testing and diabetes management. Its wholly-owned subsidiary, Microfluidic Systems, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including forward looking statements in PositiveID's interview with SmallCapVoice.com relating to molecular diagnostics and homeland defense products, including the likelihood that by entering into this teaming agreement with such a world-class company, PositiveID has positioned its unique M-BAND system to be an integral component of the upcoming $3.1 billion BioWatch Gen-3 system procurement; the likelihood that PositiveID will also maintain its role as the exclusive provider of assays and reagents under the teaming agreement for this important homeland defense program; and all other statements in this press release and PositiveID's interview with SmallCapVoice.com other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully complete development of and commercialize its diabetes management product, molecular diagnostic systems products and homeland defense products; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 28, 2012, as amended on May 4, 2012, and 10-Qs filed on November 16, 2012, August 20, 2012, as amended on September 12, 2012, and May 14, 2012, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.